Castle Creek Biosciences

Castle Creek Biosciences is a privately held, clinical-stage cell and gene therapy company using a proprietary fibroblast-based platform to develop personalized therapies for rare diseases. Its lead candidate is in a Phase 3 trial for recessive dystrophic epidermolysis bullosa, a severe genetic skin-blistering disorder. The company runs its own commercial-scale gene-therapy manufacturing facility in Exton and collaborates with the Mayo Clinic. It grew from the assets of former public company Fibrocell Science and is backed by Chicago-based Paragon Biosciences.